Client Success Story: Over €200 Million! Congratulations to I-Mab Biopharma for Successful Licensing to Sanofi — SHUIMU BIO Powers New Collaboration on CD73 Target Drugs

On September 25, 2024, SHUIMU BIO received exciting news from our client, I-Mab Biopharma: their innovative CD73-targeted cancer therapy has been successfully licensed to Sanofi, with …

Client Success Story: Over €200 Million! Congratulations to I-Mab Biopharma for Successful Licensing to Sanofi — SHUIMU BIO Powers New Collaboration on CD73 Target Drugs Read More »

Scroll to Top